Envestnet Portfolio Solutions Inc. Trims Stake in Catalent, Inc. (NYSE:CTLT)

Envestnet Portfolio Solutions Inc. lowered its position in Catalent, Inc. (NYSE:CTLT - Free Report) by 25.7% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 57,980 shares of the company's stock after selling 20,052 shares during the quarter. Envestnet Portfolio Solutions Inc.'s holdings in Catalent were worth $2,605,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently bought and sold shares of CTLT. Cadian Capital Management LP grew its position in shares of Catalent by 91.0% during the 3rd quarter. Cadian Capital Management LP now owns 5,304,784 shares of the company's stock valued at $241,527,000 after buying an additional 2,526,750 shares during the last quarter. Barclays PLC boosted its holdings in Catalent by 41.7% during the third quarter. Barclays PLC now owns 4,797,718 shares of the company's stock worth $218,440,000 after buying an additional 1,412,058 shares in the last quarter. Ameriprise Financial Inc. grew its holdings in shares of Catalent by 65.9% in the 3rd quarter. Ameriprise Financial Inc. now owns 3,483,494 shares of the company's stock worth $158,601,000 after acquiring an additional 1,384,313 shares during the last quarter. Charles Schwab Investment Management Inc. increased its stake in Catalent by 50.6% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 1,536,313 shares of the company's stock worth $69,948,000 after purchasing an additional 516,464 shares in the last quarter. Finally, Assenagon Asset Management S.A. raised its holdings in shares of Catalent by 29.6% during the third quarter. Assenagon Asset Management S.A. now owns 1,875,829 shares of the company's stock valued at $85,406,000 after acquiring an additional 428,260 shares during the period.

Analyst Ratings Changes

Several analysts have recently commented on CTLT shares. StockNews.com assumed coverage on Catalent in a research report on Monday. They issued a "sell" rating for the company. UBS Group restated a "neutral" rating and issued a $63.50 price objective (up previously from $58.00) on shares of Catalent in a report on Tuesday, February 6th. Royal Bank of Canada reissued a "sector perform" rating and issued a $63.50 target price on shares of Catalent in a research report on Tuesday, February 20th. Barclays raised their price target on shares of Catalent from $45.00 to $47.00 and gave the company an "equal weight" rating in a report on Thursday, January 25th. Finally, Stephens reissued an "equal weight" rating and set a $63.50 target price on shares of Catalent in a research report on Thursday, April 4th. Two research analysts have rated the stock with a sell rating, nine have given a hold rating and three have given a buy rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of "Hold" and an average price target of $52.46.

Catalent Trading Up 0.2 %

CTLT traded up $0.12 during trading on Friday, reaching $55.37. 1,079,315 shares of the company's stock were exchanged, compared to its average volume of 2,387,717. The company's fifty day moving average price is $56.19 and its 200-day moving average price is $49.99. The company has a debt-to-equity ratio of 1.37, a quick ratio of 1.77 and a current ratio of 2.51. The firm has a market capitalization of $10.02 billion, a PE ratio of -9.08, a P/E/G ratio of 6.71 and a beta of 1.18. Catalent, Inc. has a fifty-two week low of $31.50 and a fifty-two week high of $60.20.

Catalent (NYSE:CTLT - Get Free Report) last announced its earnings results on Wednesday, May 8th. The company reported ($0.15) earnings per share for the quarter, missing analysts' consensus estimates of $0.21 by ($0.36). Catalent had a negative return on equity of 2.73% and a negative net margin of 26.61%. The company had revenue of $1.07 billion during the quarter, compared to analyst estimates of $1.11 billion. As a group, equities analysts forecast that Catalent, Inc. will post 0.28 EPS for the current year.

Catalent Profile

Catalent, Inc, together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. It operates in two segments, Biologics, and Pharma and Consumer Health. The Biologics segment provides formulation, development, and manufacturing for biologic proteins, cell gene, and other nucleic acid therapies; pDNA, iPSCs, oncolytic viruses, and vaccines; formulation, development, and manufacturing for parenteral dose forms, including vials, prefilled syringes, and cartridges; and analytical development and testing services for large molecules.